Pharma Focus Asia

Lonza Acquires Synaffix

Thursday, June 01, 2023

Lonza, announced that it has acquired Synaffix for the development of Antibody-Drug Conjugates (ADCs). 

The acquisition of Synaffix by Lonza will enable the integration of Lonza's development and manufacturing capabilities with Synaffix's ADC technology platform. This combined offering will provide customers and licensees with a comprehensive service that covers the entire process of discovering, developing, scaling up, and commercialising novel and differentiated ADCs. 

This integration aims to offer an efficient and seamless pathway for bringing innovative ADC therapies to the market, ultimately benefiting patients in need of advanced treatment options. 

Lonza's acquisition of Synaffix highlights the strategic importance of bioconjugates within its portfolio. By bringing Synaffix into the fold, Lonza expands its offering in the rapidly growing bioconjugate market and strengthens overall value proposition for clinical customers. The combined expertise and capabilities of Lonza and Synaffix enables to position as leaders in the industry, capable of providing comprehensive support for both clinical development and commercial manufacturing needs.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024